Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT(c) Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated ...

An investigational medicine that addresses the genetic root cause of BAG3 DCM, AFTX-201 is being evaluated as a treatment for BAG3 DCM in the UPBEAT trial in the U.S. and Canada AFTX-201 is designed ...

Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Ass…

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class ...
Labmate Online

ELRIG March 2026: AAV vectors show broader promise for rare neurological, cardiac diseases

Speaking at the ELRIG meeting at Hinxton Hall in March, Dr Seng H. Cheng set out how next-generation adeno-associated viral ...

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al ...